Long-Term Assets (Annual)

Long-Term Assets: The sum of all assets classified as non-current.

Soleno Therapeutics, Inc. (SLNO) had Long-Term Assets of $208.02M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$190.41M
Net Income	$20.48M
Cost of Goods Sold	$2.70M
Gross Profit	$187.71M
Operating Expenses	$180.99M
Operating Income	$9.41M
Non-Operating Income/Expense	$11.48M
Pre-Tax Income	$20.89M
Normalized Pre-Tax Income	$20.89M
Income after Taxes	$20.89M
Income from Continuous Operations	$20.89M
Consolidated Net Income/Loss	$20.89M
Normalized Income after Taxes	$20.89M
EBIT	$9.41M
EBITDA	$11.47M
Weighted-Average Shares Outstanding (Basic)	50.82M
Weighted-Average Shares Outstanding (Diluted)	52.38M
Earnings per Share (EPS) (Basic)	$0.40
Earnings per Share (EPS) (Diluted)	$0.39
Balance Sheet Financials
Current Assets	$355.81M
Property, Plant, and Equipment	$0.18M
Long-Term Assets	$208.02M
Total Assets	$563.83M
Current Liabilities	$61.36M
Long-Term Debt	$49.86M
Long-Term Liabilities	$52.35M
Total Liabilities	$113.72M
Common Equity	$450.12M
Tangible Shareholders Equity	$445.25M
Shareholders Equity	$450.12M
Common Shares Outstanding	52.29M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$46.80M
Cash Flow from Investing Activities	$-201.78M
Cash Flow from Financial Activities	$137.16M
Beginning Cash	$87.93M
End Cash	$70.11M
Increase/Decrease in Cash	$-17.82M
Stock-Based Compensation	$45.85M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.80
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.10
Debt to Equity Ratio	0.11
Gross Margin	98.58%
Operating Margin	4.94%
EBIT Margin	4.94%
EBITDA Margin	6.02%
Pre-Tax Profit Margin	10.97%
Profit Margin	10.75%
Free Cash Flow	$46.73M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.34
Inventory Turnover	0.18
Receiveable Turnover	6.75
Days Sales in Receivables	54.07
Return on Equity	4.64%
Return on Tangible Equity	4.69%
Return on Assets	3.71%
Return on Investments	4.18%
Book Value Per Share	$8.61
Free Cash Flow per Share	$0.89
Operating Cash Flow per Share	$0.89

Data from Zacks Investment Research, Inc.